Osmotic micropumps for drug delivery

Advanced Drug Delivery Reviews

Volumn 64, Issue 14, 2012, Pages 1617-1627

  Herrlich, Simon ^a   Spieth, Sven ^a   Messner, Stephan ^a   Zengerle, Roland ^a,b  

^a Institut für Mikro und Informationstechnik der Hahn Schickard Gesellschaft E V HSG IMIT Villingen Schwenningen   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Drug delivery; MEMS; Microactuator; Microfluidics; Micropump; Osmosis; Osmotic pump; Zero order release

Indexed keywords

BUILDING BLOCKES; DRUG DELIVERY SYSTEM; DRUG-RELEASE RATE; ELECTRICAL ENERGY; MICRO PUMP; NEW APPLICATIONS; OSMOTIC AGENTS; OSMOTIC PUMPS; SITE-SPECIFIC; TRANSIT TIME; ZERO-ORDER RELEASE;

DRUG DELIVERY; MEMS; MICROACTUATORS; MICROFLUIDICS; MULTI AGENT SYSTEMS; PUMPS; SOLVENTS;

OSMOSIS;

HYDROMORPHONE; LEUPRORELIN; MORPHINE; OSMOTIC AGENT; SOLVENT; SUFENTANIL;

ADVANCED CANCER; BIOCOMPATIBILITY; BIODEGRADABILITY; BODY FLUID; BODY TEMPERATURE; CHRONIC PAIN; DEGRADATION; DRUG DELIVERY SYSTEM; DRUG POTENCY; FLOW RATE; GASTROINTESTINAL TRANSIT; HUMAN; HYDROGEL; HYDROSTATIC PRESSURE; LIPOPHILICITY; MEMBRANE PERMEABILITY; MICROELECTROMECHANICAL SYSTEM; MICROFLUIDICS; NEPHROLITHIASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOREGULATION; OSMOSIS; OSMOTIC MICROPUMP; OSMOTIC PRESSURE; OSMOTIC PUMP; PAIN; PERMEABILITY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SCANNING ELECTRON MICROSCOPY; STENT; WATER PERMEABILITY;

ANIMALS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HUMANS; MICROTECHNOLOGY; OSMOSIS; PHARMACEUTICAL PREPARATIONS;

EID: 84868194713     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.02.003     Document Type: Review

References (84)

1. Verma R.K., Mishra B., Garg S. Osmotically controlled oral drug delivery. Drug Dev. Ind. Pharm. 2000, 26:695-708.
2. Verma R.K., Arora S., Garg S. Osmotic pumps in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2004, 21:477-520.
3. Malaterre V., Ogorka J., Loggia N., Gurny R. Oral osmotically driven systems: 30 years of development and clinical use. Eur. J. Pharm. Biopharm. 2009, 73:311-323.
4. Gupta B.P., Thakur N., Jain N.P., Banweer J., Jain S. Osmotically controlled drug delivery system with associated drugs. J. Pharm. Pharm. Sci. 2010, 13:571-588.
5. Babu C.A., Rao M.P., Ratna J.V. Controlled-porosity osmotic pump tablets-an overview. J. Pharm. Res. Health Care 2010, 2:114-126.
6. Gosh T., Gosh A. Drug delivery through osmotic systems - an overview. J. Appl. Pharm. Sci. 2011, 1:38-49.
7. Santus G., Baker R.W. Osmotic drug-delivery - a review of the patent literature. J. Control. Release 1995, 35:1-21.
8. Kaushal A.M., Garg S. An update on osmotic drug delivery patents. Pharm. Technol. 2003, 7pp.
9. Rose S., Nelson J. A continuous long term injector. Aust. J. Exp. Biol. Med. Sci. 1955, 33:415-421.
10. Grattoni A., Merlo M., Ferrari M. Osmotic pressure beyond concentration restrictions. J. Phys. Chem. B 2007, 111:11770-11775.
11. Theeuwes F. Elementary osmotic pump. J. Pharm. Sci. 1975, 64:1987-1991.
12. Theeuwes F., Yum S.I. Principles of design and operation of generic osmotic pumps for delivery of semisolid or liquid drug formulations. Ann. Biomed. Eng. 1976, 4:343-353.
13. Wright J.C., Johnson R.M., Yum S.I. DUROS® osmotic pharmaceutical systems for parenteral & site-directed therapy. Drug Deliv. Technol. 2003, 3:3-11.
14. Gale R., Chandrasekaran S.K., Swanson D., Wright J. Use of osmotically active therapeutic agents in monolithic systems. J. Membr. Sci. 1980, 7:319-331.
15. Schirrer R., Thepin P., Torres G. Water-absorption, swelling, rupture and salt release in salt silicone-rubber compounds. J. Mater. Sci. 1992, 27:3424-3434.
16. Amsden B.G., Cheng Y.L., Goosen M.F.A. A mechanistic study of the release of osmotic agents from polymeric monoliths. J. Control. Release 1994, 30:45-56.
17. Amsden B. A model for osmotic pressure driven release from cylindrical rubbery polymer matrices. J. Control. Release 2003, 93:249-258.
18. Amsden B. Review of osmotic pressure driven release of proteins from monolithic devices. J. Pharm. Pharm. Sci. 2007, 10:129-143.
19. Soulas D.N., Sanopoulou M., Papadokostaki K.G. Comparative study of the release kinetics of osmotically active solutes from hydrophobic elastomeric matrices combined with the characterization of the depleted matrices. J. Appl. Polym. Sci. 2009, 113:936-949.
20. Soulas D.N., Papadokostaki K.G. Experimental investigation of the release mechanism of proxyphylline from silicone rubber matrices. J. Appl. Polym. Sci. 2011, 120:821-830.
21. Higuchi T. Mechanism of sustained-action medication - theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci. 1963, 52:1145-1149.
22. Kajihara M., Sugie T., Mizuno M., Tamura N., Sano A., Fujioka K., Kashiwazaki Y., Yamaoka T., Sugawara S., Urabe Y. Development of new drug delivery system for protein drugs using silicone (I). J. Control. Release 2000, 66:49-61.
23. Amsden B.G. Osmotically activated agent release from electrostatically generated polymer microbeads. AICHE J. 1996, 42:3253-3266.
24. Chapanian R., Amsden B.G. Osmotically driven protein release from photo-cross-linked elastomers of poly(trimethylene carbonate) and poly(trimethylene carbonate-CO-D, l-lactide). Eur. J. Pharm. Biopharm. 2010, 74:172-183.
25. Chapanian R., Amsden B.G. Combined and sequential delivery of bioactive VEGF(165) and HGF from poly (trimethylene carbonate) based photo-cross-linked elastomers. J. Control. Release 2010, 143:53-63.
26. Wiegand U.K.H., Potratz J., Bonnemeier H., Bode F., Panik R., Haase H., Peters W., Katus H.A. Long-term superiority of steroid elution in atrial active fixation platinum leads. PACE 2000, 23:1003-1009.
27. Schuchert A., Kuck K.H. Steroid eluting pacemaker electrodes - improved stimulation and sensing properties. Dtsch. Med. Wochenschr. 1992, 117:607-612.
28. Lee H., Cima M.J. An intravesical device for the sustained delivery of lidocaine to the bladder. J. Control. Release 2011, 149:133-139.
29. Natl.Inst. Health Study NCT01150565, Safety Study of LiRIS in Interstitial Cystitis (IC) Patients 27-8-2011. http://clinicaltrials.gov/ct2/show/record/NCT01150565.
30. Natl.Inst. Health Study NCT01051336, Safety and Tolerability Study of the Taris Placebo System 27-8-2011. http://clinicaltrials.gov/ct2/show/study/NCT01051336.
31. Berry S.H., Elliott M.N., Suttorp M., Bogart L.M., Stoto M.A., Eggers P., Nyberg L., Clemens J.Q. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J. Urol. 2011, 186:540-544.
32. Cima M.J. Microsystem technologies for medical applications. Annu. Rev. Chem. Biomol. Eng. 2011, 2:355-378.
33. TARIS Biomedical, Inc. 27-8-2011. http://www.tarisbiomedical.com/our_tech.php.
34. Scholz O.A., Wolff A., Schumacher A., Giannola L.I., Campisi G., Ciach T., Velten T. Drug delivery from the oral cavity: focus on a novel mechatronic delivery device. Drug Discov. Today 2008, 13:247-253.
35. Goettsche T., Schumacher A., Kohnle J., Messner S., Zengerle R. Highly integrated oral drug delivery system with valve based on electro-active-polymer. Proc. of MEMS2007, Kobe 2007, 461-464.
36. Goettsche T., Haeberle S. Integrated oral drug delivery system with valve based on polypyrrole. Biomedical Applications of Electroactive Polymer Actuators 2009, 301-316. John Wiley & Sons, Ltd., Chichester. F. Carpi, E. Smela (Eds.).
37. Velten T., Knoll T., Haberer W., Koch T., Scholz O. Biocompatible flow sensor with integrated solvent concentration measurement. Sens. Actuators, A 2008, 145:257-262.
38. Giannola L.I., Paderni C., De Caro V., Florena A.M., Wolff A., Campisi G. New prospectives in the delivery of galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies. Curr. Pharm. Des. 2010, 16:653-659.
39. Moscicka A.E., Czarnecka K., Ciach T. IntelliDrug implant for medicine delivery in Alzheimer's disease treatment. Macromol. Symp. 2007, 253:134-138.
40. Ciach T. Intraoral implant for drug delivery in addiction and chronic disease treatment. Inz. Chem. Procesowa 2007, 28:559-565.
41. Campisi G., Giannola L.I., Florena A.M., De Caro V., Schumacher A., Gottsche T., Paderni C., Wolff A. Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs. J. Control. Release 2010, 145:214-220.
42. Schumacher A., Goettsche T., Haeberle S., Velten T., Scholz O., Wolff A., Beiski B., Messner S., Zengerle R. Intraoral drug delivery microsystem. ECIFMBE 2008, IFMBE Proceedings 2008, 22:2352-2355. Springer, Berlin Heidelberg.
43. Voskerician G., Shive M.S., Shawgo R.S., von Recum H., Anderson J.M., Cima M.J., Langer R. Biocompatibility and biofouling of MEMS drug delivery devices. Biomaterials 2003, 24:1959-1967.
44. Langer R. Drug delivery and targeting. Nature 1998, 392:5-10.
45. Nair L.S., Laurencin C.T. Biodegradable polymers as biomaterials. Prog. Polym. Sci. 2007, 32:762-798.
46. Ryu W.H., Huang Z.N., Prinz F.B., Goodman S.B., Fasching R. Biodegradable micro-osmotic pump for long-term and controlled release of basic fibroblast growth factor. J. Control. Release 2007, 124:98-105.
47. Ryu W.H., Vyakarnam M., Greco R.S., Prinz F.B., Fasching R.J. Fabrication of multi-layered biodegradable drug delivery device based on micro-structuring of PLGA polymers. Biomed. Microdevices 2007, 9:845-853.
48. Tobias I.S., Lee H., Engelmayr G.C., Macaya D., Bettinger C.J., Cima M.J. Zero-order controlled release of ciprofloxacin-HCl from a reservoir-based, bioresorbable and elastomeric device. J. Control. Release 2010, 146:356-362.
49. ALZET® Osmotic Pumps 27-8-2011. http://www.alzet.com.
50. Wright J. Ruminal osmotic bolus. Encyclopedia of Controlled Drug Delivery 1999, 915-920. Wiley, New York. E. Mathiowitz (Ed.).
51. ® bolus. J. Control. Release 1997, 47:1-11.
52. Brayden D.J., Oudot E.J.M., Baird A.W. Drug delivery systems in domestic animal species. Handb. Exp. Pharmacol. 2010, 79-112.
53. Fowler J.E., Gottesman J.E., Bardot S.F., Reid C., Andriole G.L., Bernhard P.H., Rivera-Ramirez I., Libertino J.A., Soloway M.S. Duros™ leuprolide implantable therapeutic systems in patients with advanced prostate cancer: 14-month results of a phase I/II dose-ranging study. J. Urol. 1999, 161.
54. Fowler J.E., Gottesman J.E., Bardot S.F., Reid C.F., Andriole G.L., Bernhard P.H., Rivera-Ramirez I., Libertino J.A., Soloway M.S. A phase I/II dose ranging study of DUROS™ (leuprolide) implantable therapeutic system in patients with advanced prostate cancer. J. Urol. 1998, 159:335.
55. Cukierski M.J., Johnson P.A., Beck J.C. Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs. Int. J. Toxicol. 2001, 20:369-381.
56. Fowler J.E., Group M.S. Use of the DUROS® leuprolide implant in patients with prostate cancer: efficacy and safety results from two long-term phase I/II and III studies. J. Urol. 2000, 163:262-263.
57. Fowler J.E., Gottesman J.E., Reid C.F., Andriole G.L., Soloway M.S. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J. Urol. 2000, 164:730-734.
58. Wright J.C., Leonard S.T., Stevenson C.L., Beck J.C., Chen G.H., Jao R.M., Johnson P.A., Leonard J., Skowronski R.J. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J. Control. Release 2001, 75:1-10.
59. Wright J.C. Critical variables associated with nonbiodegradable osmotically controlled implants. AAPS J. 2010, 12:437-442.
60. Fowler J.E., Flanagan M., Gleason D.M., Klimberg I.W., Gottesman J.E., Sharifi R. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urology 2000, 55:639-642.
61. Fowler J.E. Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer. Urology 2001, 58:430-434.
62. Bayer AG Bayer Annual Report 2006 27-8-2011. http://www.bayer.com/en/GB-2006-en.pdfx.
63. Staples M. Microchips and controlled-release drug reservoirs. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2:400-417.
64. Fisher D.M., Kellet N., Lenhardt R. Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. Anesthesiology 2003, 99:929-937.
65. Henry R.R., Cuddihy R., Rosenstock J., Alessi T., Luskey K. Comparing ITCA 650, continuous subcutaneous delivery of exenatide via DUROS device, vs. twice daily exenatide injections in metformintreated type 2 diabetes. Diabetologia 2010, 53:78.
66. Rohloff C.M., Alessi T.R., Yang B., Dahms J., Carr J.P., Lautenbach S.D. DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months. J. Diab. Sci. Technol. 2008, 2.
67. Wright J.C., Culwell J. Long-term controlled delivery of therapeutic agents by the osmotically driven DUROS® implant. Modified-Release Drug Delivery Technology 2008, 143-149. Informa Healthcare, New York. M.J. Rathbone, J. Hadgraft, M.S. Roberts (Eds.).
68. Intarcia Therapeutics, Inc. 27-8-2011. http://www.intarcia.com.
69. Herrlich S., Spieth S., Nouna R., Zengerle R., Giannola L.I., Pardo-Ayala D.E., Federico E., Garino P. Ambulatory Treatment and Telemonitoring of Patients with Parkinson's Disease 2011, 295-305. Springer, Dordrecht. R. Wichert, B. Eberhardt (Eds.).
70. Herrlich S., Lorenz T., Marker M., Spieth S., Messner S., Zengerle R. Miniaturized osmotic pump for oromucosal drug delivery with external readout station. Proc. of IEEE-EMBC, Boston 2011, 8380-8383.
71. Li Y.H., Su Y.C. Miniature osmotic actuators for controlled maxillofacial distraction osteogenesis. J. Micromech. Microeng. 2010, 20:065013.
72. Su Y.C., Lin L.W. A water-powered micro drug delivery system. J. Microelectromech. Syst. 2004, 13:75-82.
73. Su Y.C., Lin L.W., Pisano A.P. A water-powered osmotic microactuator. J. Microelectromech. Syst. 2002, 11:736-742.
74. Deem T., Ligrani P.M., Tower D., Connelly J. Osmotic dispense pump for operation at different temperatures and pressures. Sens. Actuators, A 2007, 136:742-748.
75. Ehwald M., Adleff H., Geggier P., Ehwald R. A long-term stable and adjustable osmotic pump for small volume flow based on principles of phloem loading. Biotechnol. Bioeng. 2006, 94:37-42.
76. Soppimath K.S., Aminabhavi T.M., Dave A.M., Kumbar S.G., Rudzinski W.E. Stimulus-responsive "smart" hydrogels as novel drug delivery systems. Drug Dev. Ind. Pharm. 2002, 28:957-974.
77. Eddington D.T., Beebe D.J. A hydrogel actuated microdispensing device. Proc. of EMBS/BMES 2002, 1824-1825.
78. Eddington D.T., Beebe D.J. A valved responsive hydrogel microdispensing device with integrated pressure source. J. Microelectromech. Syst. 2004, 13:586-593.
79. Eddington D.T., Beebe D.J. Development of a disposable infusion system for the delivery of protein therapeutics. Biomed. Microdevices 2005, 7:223-230.
80. Good B.T., Bowman C.N., Davis R.H. A water-activated pump for portable microfluidic applications. J. Colloid Interface Sci. 2007, 305:239-249.
81. Suzuki H., Tokuda T., Miyagishi T., Yoshida H., Honda N. A disposable on-line microsystem for continuous sampling and monitoring of glucose. Sens. Actuators, B 2004, 97:90-97.
82. Xu Z.R., Yang C.G., Liu C.H., Zhou Z., Fang J., Wang J.H. An osmotic micro-pump integrated on a microfluidic chip for perfusion cell culture. Talanta 2010, 80:1088-1093.
83. Richter A., Klenke C., Arndt K.F. Adjustable low dynamic pumps based on hydrogels. Macromol. Symp. 2004, 210:377-384.
84. Greiner R., Klatt S., Allerdissen M., Richter A. Microfluidic devices and systems based on intrinsically active polymers. Proc. of Actuator, Bremen 2010, 228-233.